logo
ResearchBunny Logo
Abstract
This study investigates a novel nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues to elicit robust antitumor T cell responses. Using KRAS G12D mutations as neoantigens, the researchers found that vaccination with SLP-Lpx (synthetic long peptides in cationic lipoplexes) stimulated both CD4⁺ and CD8⁺ T cells, suppressing tumor growth in a CD8⁺ T cell-dependent manner, more effectively than naked synthetic peptides. Combining SLP-Lpx vaccines with a checkpoint inhibitor led to significant tumor growth suppression, suggesting that targeted delivery of neoantigen-derived peptides to the spleen via lipoplexes enhances antitumor immunity.
Publisher
npj Vaccines
Published On
Nov 12, 2020
Authors
Carlos A. Arbeláez, Juan Estrada, Melissa A. Gessner, Charles Glau, Agnieszka B. Morales, Deanna Mohn, Hyewon Phee, J. Russell Lipford, James A. Johnston
Tags
nanoparticle vaccine
neoantigen peptides
antitumor T cell responses
KRAS G12D mutations
SLP-Lpx
tumor growth suppression
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs—just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny